|Table of Contents|

Calculation of the association between tumor clinical efficacy and long-term health benefits:A case study of a blood tumor

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 04
Page:
636-640
Research Field:
Publishing date:

Info

Title:
Calculation of the association between tumor clinical efficacy and long-term health benefits:A case study of a blood tumor
Author(s):
LIU Chang1; TAO Libo1; 2; WU Yao1; WANG Fangxu1; YAN Yi1; SUN Shuang1
1.Center for Health Policy and Technology Evaluation,Peking University Health Science Center,Beijing 100191,China;2.Department of Health Policy and Management,School of Public Health,Peking University,Beijing 100191,China.
Keywords:
long-term health benefits; clinical efficacy; association calculation; r/r B-ALL
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2025.04.013
Abstract:
Objective:To measure and present the numerical relationship between clinical efficacy and long-term health benefits of tumor treatment.Methods:Taking relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) as an example,a Markov model was established with standard chemotherapy as the treatment scenario to calculate the incremental quality-adjusted life years (QALYs) that would result from unit improvement of the two efficacy indicators,median overall survival (mOS) and median relapse-free survival (mRFS),and to conduct sensitivity analysis.Results:The QALYs of r/r B-ALL patients increased by 0.073 8 per month for mRFS and 0.054 4 per month for mOS after treatment.Sensitivity analysis suggests that the results are robust.Conclusion:By establishing an appropriate measurement method,the clinical efficacy and long-term health benefits of r/r B-ALL patients can be quantified and calculated,so as to support related health decisions more efficiently and quickly.

References:

［1］ 姚一菲,孙可欣,郑荣寿.《2022全球癌症统计报告》解读：中国与全球对比［J］.中国普外基础与临床杂志,2024,31(07):769-780. YAO YF,SUN KX,ZHENG RS.《2022 Global Cancer Statistics Report》Interpretation:China versus the world［J］.Chinese Journal of Bases and Clinics in General,2024,31(07):769-780.
［2］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［3］ 李丽,高莹苒,王大勇,等.嵌合抗原受体(CAR)技术在血液肿瘤治疗中的研究进展［J］.河南大学学报（医学版）,2016,35(4):290-293. LI L,GAO YR,WANG DY,et al.Research progress of chimeric antigen receptor (CAR) technology in the treatment of hematologic tumors［J］.Journal of Henan University (Medical Edition),2016,35(4):290-293.
［4］ 罗成伟,杜欣,郭荣,等.伊曲康唑注射液在血液肿瘤患者经验性抗真菌治疗的临床研究［J］.中国实验血液学杂志,2012,20(4):1000-1004. LUO CW,DU X,GUO R,et al.Clinical study of Itraconazole injection in the empirical antifungal treatment of patients with hematologic tumors［J］.Journal of Experimental Hematology,2012,20(4):1000-1004.
［5］ 于果.抗血管新生治疗在血液肿瘤治疗中的应用效果评价［J］.中国医药指南,2015,13(34):108-109. YU G.Evaluation of the efficacy of antiangiogenesis therapy in the treatment of blood tumors［J］.Guide of China Medicine,2015(34):108-109.
［6］ 高惟芳.CD19-CAR-T细胞治疗复发/难治性急性淋巴细胞白血病及复发/难治弥漫大B细胞淋巴瘤临床观察［D］.赣州：赣南医科大学,2024. GAO WF.Clinical observation of CD19-CAR T cells in the treatment of relapsed/refractory acute lymphoblastic leukemia and relapsed/refractory diffuse large B-cell lymphoma［D］.Ganzhou:Gannan Medical University,2024.
［7］ 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南（2024年版）［J］.中华血液学杂志,2024,45(5):417-429. Hematologic Oncology Committee,Chinese Anti-Cancer Association,Leukemia and Lymphoma Group,Hematology Branch,Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of adult acute lymphoblastic leukemia (2024 edition) ［J］.Chinese Journal of Hematology,2024,45(5):417-429.
［8］ 马国强,郑淼淼,洪望龙,等.奥加伊妥珠单抗用于难治或复发性B细胞急性淋巴细胞白血病的成本效用分析［J］.中国医院药学杂志,2023,43(20):2275-2279. MA GQ,ZHENG MM,HONG WL,et al.Cost-effectiveness analysis of ogaituzumab for refractory or recurrent B-cell acute lymphoblastic leukemia［J］.Chinese Journal of Hospital Pharmacy,2023,43(20):2275-2279.
［9］ KANTARJIAN HM,DEANGELO DJ,STELLJES M,et al.Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia:Final report and long-term survival follow-up from the randomized,phase 3 INO-VATE study［J］.Cancer,2019,125(14):2474-2487.
［10］ KANTARJIAN H,STEIN A,GKBUGET N,et al.Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia［J］.N Engl J Med,2017,376(9):836-847.
［11］ 周挺,马爱霞,付露阳.药物经济学评价Markov模型中转移概率计算的探讨［J］.中国卫生经济,2017,36(12):40-42. ZHOU T,MA AX,FU LY.Discussion on transfer probability calculation in Markov model of pharmacoeconomic evaluation［J］.Chinese Health Economics,2017,36(12):40-42.
［12］ 凌鑫,林秀文,张莹,等.2015-2021年我国城乡居民死亡状况分析［J］.疾病监测,2024,39(3):369-375. LING X,LIN XW,ZHANG Y,et al.Death status analysis of urban and rural residents in China from 2015 to 2021［J］.Disease Surveillance,2024,39(3):369-375.
［13］ 中国疾病预防控制中心，慢性非传染性疾病预防控制中心，国家卫生健康委统计信息中心.中国死因监测数据集［M］.北京：中国科学技术出版社,2022:77. Chinese Center for Disease Control and Prevention,Center for Chronic Noncommunicable Disease Control and Prevention,National Health Commission Statistics and Information Center.Chinese cause-of-death surveillance dataset［M］.Beijing:Science and Technology Press of China,2022:77.
［14］ 胡宏飞,周挺,李冯,等.健康价值评估中质量调整生命年的替代及优化方法介绍与比较［J］.中国新药杂志,2024,33(19):1969-1975. HU HF,ZHOU T,LI F,et al.Introduction and comparison of alternative and optimization methods of quality-adjusted life years in health value assessment［J］.Chinese Journal of New Drugs,2024,33(19):1969-1975.
［15］ LEE TY,CHEN HY,CHEN TY,et al.Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system［J］.Eur J Health Econ,2020,21(7):1105-1116.
［16］ 刘国恩.中国药物经济学评价指南［M］.北京:中国市场出版社,2020:16-17. LIU GE.China guidelines for pharmacoeconomic evaluations［M］.Beijing:China Market Press,2020:16-17.

Memo

Memo:
-
Last Update: 1900-01-01